曲妥珠单抗在乳腺癌新辅助化疗中的应用  

The application of trastuzumab in neoadjuvant chemotherapy in patients with breast cancer

作　　者：李丽[1] 秦建伟[1] 韦达[1] 吴建中[1] 唐金海[1] 

机构地区：[1]江苏省肿瘤医院普外科,江苏南京210009

出　　处：《肿瘤》2014年第11期1058-1063,共6页Tumor

基　　金：2010年度"六大人才高峰"D类资助项目(编号:2010-WS-075)

摘　　要：人类表皮生长因子受体2（human epidermal growth factor receptor 2,HER-2）蛋白在20%~25%的乳腺癌患者中呈过度表达状态,其过表达与肿瘤侵袭性强、复发率高和死亡率高密切相关。曲妥珠单克隆抗体（简称曲妥珠单抗）作为人源化抗HER-2单抗,通过多种机制表现出其对乳腺癌具有较好的疗效。目前,曲妥珠单抗已被常规应用于乳腺癌患者的手术后辅助化疗或转移性乳腺癌的治疗。手术前应用新辅助曲妥珠单抗联合化疗也可使HER-2阳性的乳腺癌患者从中受益,本文对此类新辅助化疗的疗效及不良反应进行了总结分析。Over-expression of human epidermal growth factor receptor 2（HER-2） protein is available in 20% to 25% of patients with breast cancer,and it is associated with serious aggressiveness,high recurrence rate,and increased mortality of cancer.Trastuzumab,a humanized antibody against HER-2,has shown high effi cacy in breast cancer through multiple mechanisms.Currently,trastuzumab is used in adjuvant therapy for breast cancer or in metastatic settings.Trials of trastuzumab in combination with chemotherapy suggest that patients with HER-2-positive breast cancer also may benefit from this neoadjuvant chemotherapy.This article reviews the effi cacy and adverse effects of trastuzumab in neoadjuvant chemotherapy for breast cancer.

关 键 词：乳腺肿瘤 新辅助疗法 基因 erb B-2 曲妥珠单抗 

分 类 号：R737.9[医药卫生—肿瘤]